Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

nts with chronic pain."

Additional Study Results

  • Assessment of "Feeling High"
  • All oral doses of NKTR-181 scored similar to placebo in a Drug Effects Questionnaire (DEQ) assessing the treatment's effect on how "high" the subject felt (on a scale of 0 (not at all) to 100 (extremely)).  Oxycodone oral solution resulted in a maximum mean DEQ score of 81.
    NKTR-181 maximum mean DEQ scores were 14, 14 and 23 for 100 mg, 200 mg tablet and 400 mg, respectively, with p-values < 0.0001 as compared to oxycodone.  Placebo achieved a maximum mean DEQ score of 9. 

  • Assessment of "Sleepiness"
  • Sedation was measured using a DEQ assessment of sleepiness (on a scale of 0 (not at all) to 100 (extremely).  All doses of NKTR-181 scored lower on sleepiness when compared to oxycodone.  The maximum mean DEQ sleepiness score for oxycodone was 44 as compared to the maximum mean DEQ scores for NKTR-181 100 mg, 200 mg and 400 mg of 10, 9, and 18, respectively (p<0.0001). 

    Study DesignThe randomized, double-blind, placebo- and active-controlled, 5-way crossover trial, compared the effects of three doses of NKTR-181 oral solution (100 mg, 200 mg, and 400 mg), to the effects of 40 mg of oxycodone oral solution and placebo.  Participants were healthy adults (N=42) who were not currently physically opioid-dependent but had used opioids to attain non-medical effects on at least 10 occasions during the past year and at least once in the 12 weeks before the study.  Study participants sequentially received the five treatments, administered in a randomized, double-blinded fashion, with each treatment separated by a washout period.  The study also utilized a Williams Square cross-over design, which uses a series of randomized sequences for each individual subject.

    About NKTR-181 NKTR-181 is currently being evaluated in Phase 2 development as a twice-daily oral tablet to treat chronic
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
    2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
    3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
    4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
    5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
    6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
    7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
    8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
    9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... 2014 North American lighting leader OSRAM SYLVANIA ... for the new OSRAM ITOS ® PHASER ® ... for microscopy, endoscopy and surgical head lamps that delivers the ... and lamp life. "We,re honored to be recognized ... innovative new technologies of the past year," said Andreas ...
    (Date:8/27/2014)... 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... pharmaceutical development, clinical trial manufacturing, and advanced analytical and ... it will participate at the upcoming Rodman & Renshaw ... held in New York . The ... September 9, 2014 at the New York Palace Hotel. ...
    (Date:8/27/2014)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the same ... the quarter of $240,156 compared to net income of $238,826 ... For the nine months ended June 30, 2014: ...
    Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
    ... March 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company update at the Barclays ... at 4:15 p.m. ET.   Interested parties may ... the investor section of the BioMarin website, www.BMRN.com . ...
    ... (Nasdaq: VRML ) –Vermillion, a molecular ... data from its collaboration with Johns Hopkins University School ... specificity of CA125 for the identification of malignant ovarian ... Meeting on Women,s Cancer of the Society of Gynecologic ...
    Cached Medicine Technology:BioMarin to Present at the Barclays Global Healthcare Conference 2Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test 2Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test 3
    (Date:8/27/2014)... The American College of ... management and treatment of pulmonary arterial hypertension (PAH) ... in Adults: CHEST Guideline, in the journal CHEST. ... and provide the latest and most accurate treatment ... Association (PHA) – the country’s leading pulmonary ...
    (Date:8/27/2014)... HealthDay Reporter WEDNESDAY, Aug. 27, 2014 (HealthDay ... alley will likely never want to return there, having associated ... neuroscientists working with mice say they,ve discovered the brain circuit ... emotions. And in rodent tests, they,ve manipulated brain cells to ... they made once-reluctant mice want to return to that dark ...
    (Date:8/27/2014)... MI (PRWEB) August 27, 2014 Michigan Head ... help the children of a local elementary school by ensuring ... Siersma Elementary School has year-round attendance, and Michigan Head & ... to meet the new school year. , "There are a ... this is a great way to give back to our ...
    (Date:8/27/2014)... The federal judge overseeing thousands of ... the deadline for plaintiffs to enroll in the U.S. ... by U.S. District Judge David Katz of the Northern ... DePuy ASR Settlement Program must do so by September ... Implant Products Liability Litigation – MDL 2197) , “Our ...
    (Date:8/27/2014)... News) -- Pouring half a glass of wine at a time ... study. Researchers asked 74 college students and staff to pour ... had varying amounts of wine in them. The participants were told ... a "rule of thumb" about how much to pour -- such ... the top -- poured less wine than those without set guidelines. ...
    Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
    ... Center,s Average ER Wait TimePANAMA CITY, Fla., May 21 ... area to find out the average ER wait time at ... The hospital is posting its average ER wait times ... became the only hospital in our area to post our ...
    ... opened door to NUHW organizing effortOAKLAND, Calif., May 21 ... the recent decision by the California Public Employee Relations ... Medical Center (DMC) in San Pablo to continue. The ... violations of labor law by DMC management and organizers ...
    ... span in mice may hold hope for people, , , THURSDAY, ... discovered a way to boost chemotherapy and slightly extend the ... for more effective treatments in people. , There,s no guarantee ... it did, the researchers don,t expect that it would add ...
    ... and Financing Offerings Help Healthcare Providers to Accelerate ... May 21 Perot Systems Corporation (NYSE: ... today announced the availability of financing options to ... implementation of electronic health records which are being ...
    ... Committee, the region,s most prominent business organization, today applauded ... Board report in Atlanta, Georgia. Greater Baltimore Committee ... Board process has been of great value to the ... is appreciated by the business community. He is ...
    ... health and economic data like you,ve never seen it ... Hans Rosling will show how reproductive health ... will also illustrate how the convergence of conditions around ... "Western" and "developing" categories an outdated concept.On Tuesday, ...
    Cached Medicine News:Health News:ER Wait Times at Your Fingertips 2Health News:Doctors Medical Center Election Tainted 2Health News:A New Way to Get Chemo to Pancreatic Tumors 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 3Health News:Gapminder's Hans Rosling Brings Poverty, Health Data to Life at Wilson Center 2
    Modified Freer periosteal elevator, #163, slight curve, 21 cm....
    Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
    Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
    Periosteal elevator #9H, 17.5 cm, 7"....
    Medicine Products: